

Ercros presents its portfolio of pharmaceutical products at the international trade fair CPHI Frankfurt



Ercros participates this week in CPHI Frankfurt 2025, the main international meeting of the pharmaceutical sector, which brings together the largest manufacturers and distributors of active ingredients and intermediate products in the world. Ercros has its own stand, from which it presents its portfolio of generic active pharmaceutical ingredients (APIs), mostly antibiotics, along with anti-hypertensive and anti-ulcer products.

Among the products highlighted in this edition are gentamycin sulfate, recently added to the Ercros portfolio, and vancomycin HCL, which is scheduled to be launched in 2026. Both products reinforce the company's position in the segment of antibiotics for hospital use, with great technical complexity and high added value.

The pharmaceuticals division of Ercros specialises in biological manufacturing, which includes strain research and maintenance, microbiological control, fermentation and industrial extraction. It also has a production line for chemical synthesis and sterile products. In addition, it develops custom APIs and intermediates for customers looking for tailor-made solutions.

Ercros exports more than 90% of its API sales to about 50 countries on all continents. Its main markets include Italy, India, Turkey, France, Japan and Switzerland, where its customers, laboratories and distributors use Ercros APIs and intermediates as raw materials for the manufacture of commercial pharmaceutical specialties.

With its participation in CPHI Frankfurt, Ercros reaffirms its commitment to quality, innovation and sustainability in the pharmaceutical field, consolidating its position as a global reference supplier of generic active ingredients.

For more information about Ercros' pharmaceuticals division, [click here](#).

Barcelona, October 30, 2025